{"nct_id":"NCT04109066","title":"Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer","status":"COMPLETED","status_verified_date":"2024-12","start_date":"2019-11-18","start_date_type":"ACTUAL","primary_completion_date":"2023-01-16","primary_completion_date_type":"ACTUAL","completion_date":"2023-12-27","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["BMY"]}